Is Moderna Stock A Buy On A New Suite Of Vaccines Targeting Flu, RSV, Cancer?

stock is under pressure after the company reported mixed results for its messenger RNA-based flu shot. The company tested its shot in North America. While the shot proved superior to a licensed competitor when it comes to influenza strain A — and on par with the traditional shot when it comes to B…#rna #moderna #stephanebancel #senatecommittee #pfe #fda #rsv #pfizer #gsk #generationbio
Source: Reuters: Health - Category: Consumer Health News Source Type: news